Turing Pharmaceuticals
Latest Stories
martin_shkreli_trial_15364.jpg
FILE- In this June 19, 2017 file photo, former Turing Pharmaceuticals CEO, Martin Shkreli, center, arrives at Brooklyn federal court in New York with members of his legal team. Jurors heard testimony from the government's last witness on Tuesday, July 25, 2017, a day after Shkreli's lawyer told the court his client won't take the witness stand during his securities fraud trial. (AP Photo/Mark Lennihan, File)
martin_shkreli_trial_07764.jpg
FILE - In this June 26, 2017, file photo, former Turing Pharmaceuticals CEO Martin Shkreli, left, arrives at federal court with his attorney Benjamin Brafman in New York. The jury at the securities fraud trial of "Pharma Bro" Martin Shkreli has heard investors accuse the quirky former biotech CEO of repeatedly giving them the runaround when they tried to pull their money out of his failing health care hedge fund. But the government witnesses have made a concession that the defense hopes plays in its favor: In the end, they made a killing. (AP Photo/Seth Wenig, file)
martin_shkreli_trial_96537.jpg
FILE- In this June 26, 2017, file photo, former Turing Pharmaceuticals CEO Martin Shkreli arrives to federal court in New York. Prosecutors filed a motion in U.S. District Court on Monday, July 3, asking that Shkreli and attorneys for all parties refrain from making statements outside court. (AP Photo/Seth Wenig, File)
martin_shkreli_trial_34718.jpg
Former Turing Pharmaceuticals CEO Martin Shkreli, left, arrives to federal court with his attorney Benjamin Brafman in New York, Monday, June 26, 2017. Even with his federal securities fraud trial set to begin Monday, Shkreli has blatantly defied his attorneys' advice to lay low. (AP Photo/Seth Wenig)
martin_shkreli_trial_02674.jpg
Former Turing Pharmaceuticals CEO Martin Shkreli arrives to federal court in New York, Monday, June 26, 2017. Even with his federal securities fraud trial set to begin Monday, Shkreli has blatantly defied his attorneys' advice to lay low. (AP Photo/Seth Wenig)
martin_shkreli_trial_54914.jpg
FILE - In this Monday, June 19, 2017, file photo, former Turing Pharmaceuticals CEO Martin Shkreli, second from right, arrives at Brooklyn federal court with members of his legal team, in New York, for a pretrial conference in his securities fraud trial. Shkreli's trial begins Monday, June 26, 2017. (AP Photo/Mark Lennihan, File)
martin_shkreli_trial_28958.jpg
Former Turing Pharmaceuticals CEO Martin Shkreli, left, arrives to federal court with his attorney Benjamin Brafman in New York, Monday, June 26, 2017. Even with his federal securities fraud trial set to begin Monday, Shkreli has blatantly defied his attorneys' advice to lay low. (AP Photo/Seth Wenig)
aptopix_martin_shkreli_trial_67039.jpg
Former Turing Pharmaceuticals CEO Martin Shkreli, left, arrives to federal court with his attorney Benjamin Brafman, in New York, Monday, June 26, 2017. Even with his federal securities fraud trial set to begin Monday, Shkreli has blatantly defied his attorneys' advice to lay low. (AP Photo/Seth Wenig)
martin_shkreli_trial_06485.jpg
Former Turing Pharmaceuticals CEO Martin Shkreli, left, arrives to federal court with his attorney Benjamin Brafman in New York, Monday, June 26, 2017. Even with his federal securities fraud trial set to begin Monday, Shkreli has blatantly defied his attorneys' advice to lay low. (AP Photo/Seth Wenig)
martin_shkreli_trial_44105.jpg
In this Monday, June 19, 2017, file photo, former Turing Pharmaceuticals CEO Martin Shkreli arrives at Brooklyn federal court with members of his legal team, in New York, for a pretrial conference in his securities fraud trial. Shkreli's trial begins Monday, June 26. (AP Photo/Mark Lennihan, File)
college_speakers_protesters_45360.jpg
In this Feb. 4, 2016 file photo, pharmaceutical chief Martin Shkreli speaks on Capitol Hill in Washington during the House Committee on Oversight and Reform Committee hearing on a decision by his former company, Turing Pharmaceuticals, to significantly raise the price of the anti-parasitic medication Daraprim. Heated protests at the University of California, Davis brought the cancellation of planned speeches by far-right commentator Milo Yiannopoulos and former pharmaceutical executive Shkreli shortly before the event was to begin. University police put up barricades as protesters shouting "shut it down" grew increasingly rowdy in the hours leading up to the talks on Friday night, Jan. 13, 2017. (AP Photo/Susan Walsh, File)
drug_prices-company_schemes.jpeg
In this Wednesday, Feb. 3, 2016, file photo, former Turing Pharmaceuticals CEO Martin Shkreli leaves court in New York. The same strategy that Shkreli used to get away with a 5,000-percent price increase on an old drug is used by many other drugmakers to maintain sky-high prices on billions of dollars’ worth of medications. (AP Photo/Seth Wenig, File)
drug_price_hikes-congress.jpeg
Former Turing Pharmaceuticals CEO Martin Shkreli is interviewed by host Maria Bartiromo during her "Mornings with Maria Bartiromo" program on the Fox Business Network, in New York, Tuesday, Feb. 2, 2016. (AP Photo/Richard Drew) ** FILE **
kalobios-shkreli_fired.jpeg
In this Dec. 17, 2015 file photo, Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is escorted by law enforcement agents in New York after being taken into custody following a securities probe. Shkreli resigned as the head of Turing Pharmaceuticals, one of the companies he runs, and another, KaloBios Pharmaceuticals, said Monday, Dec. 21, in a printed statement that it terminated Shkreli last week.. (AP Photo/Craig Ruttle, File)
Shkreli Resignation.JPEG-0fc0d.jpg
FILE - In this Dec. 17, 2015 file photo, Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is escorted by law enforcement agents in New York after being taken into custody following a securities probe. Shkreli has resigned as the head of one of the companies he now runs, Turing Pharmaceuticals, on Friday, Dec. 18, 2015.(AP Photo/Craig Ruttle)
ARREST.jpg
AIDS activists pour cat litter on an image of Turing Pharmaceuticals CEO Martin Shkreli in a makeshift cat litter pan during a protest highlighting pharmaceutical drug pricing in New York, in this Oct. 1, 2015, file photo. Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is in custody following a securities probe, Thursday, Dec. 17, 2015. (AP Photo/Craig Ruttle)
